ArticleThe international journal of neuropsychopharmacology2026
High-density EEG study in patients with schizophrenia treated with cariprazine.
Article in The international journal of neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- External validation as the critical step for predictive biomarkers.The international journal of neuropsychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSchizophrenia is marked by persistent negative and cognitive symptoms that remain difficult to treat. Cariprazine, a dopamine D3/D2 partial agonist, has demonstrated efficacy in these domains, making it essential to clarify its neurophysiological mechanisms both for future drug discovery and clinical application. Resting-state EEG spectral analysis provides a non-invasive and translational tool for monitoring neurophysiological changes related to treatment. However, data on EEG spectral effects in human patients treated with cariprazine are currently lacking.
methodsIn this open-label investigation, 27 patients with schizophrenia underwent high-density resting-state EEG before and during cariprazine treatment. Power spectral analyses were conducted across frequency bands and cortical regions, with ROI analyses targeting gamma-activity in DLPFC, IFG, and TPJ. Symptom changes were measured using the Positive and Negative Syndrome Scale.
resultsCariprazine treatment led to symptom improvement, particularly in negative and general domains. EEG analyses showed increased spectral power, most prominently in the theta and alpha bands, mirroring findings from the only available in vivo preclinical study, which also reported theta and alpha elevations in rodents. Symptom reduction was specifically associated with increased theta and decreased delta power. Moreover, baseline gamma-activity-especially in the IFG and DLPFC-predicted treatment response, with Receiver Operating Characteristic analyses yielding AUC values of 0.72-0.92 and cross-validated classification accuracies exceeding 70%.
conclusionsTogether, our results demonstrate that resting-state EEG spectral measures reflect neurophysiological correlates of cariprazine response. Furthermore, the findings reinforce the cross-species translatability of spectral measures and support EEG biomarkers as promising translational tools for predicting and monitoring treatment outcomes in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.